SCHEMBL15760363

SCHEMBL15760363

CB(O)N1C[C@H](O)C[C@H]1C(C)=O

nearest known ligand 0.43

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.43
DPP4 P27487 6/20 0.33
DPP8 Q6V1X1 6/20 0.33
DPP9 Q86TI2 6/20 0.33
DPP7 Q9UHL4 1/20 0.32
FAP Q12884 1/20 0.32
PIK3CD O00329 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12795649 0.85 ATM (0.52) ATMDPP4DPP8DPP9DPP7
SCHEMBL7806430 0.85 ATM (0.52) ATMDPP4DPP8DPP9DPP7
SCHEMBL85622 0.85 ATM (0.52) ATMDPP4DPP8DPP9DPP7
SCHEMBL15760313 0.85 ATM (0.32) ATM
SCHEMBL2610758 0.80 ALDH1A1 (0.46) ATM
SCHEMBL16376157 0.80 ALDH1A1 (0.46) ATM
SCHEMBL2608451 0.80 ALDH1A1 (0.46) ATM
SCHEMBL18084393 0.80 ALDH1A1 (0.46) ATM
SCHEMBL13661911 0.80 ALDH1A1 (0.46) ATM
SCHEMBL13920579 0.76 KMT2A (0.34) ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170050942-A1 3-CYCLOALKYLAMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS INCYTE CORP (US) 2017-02-23 US disclosed
US-20150231114-A1 3-CYCLOALKYLAMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS PFIZER (US) 2015-08-20 US disclosed
US-20140155377-A1 3-CYCLOALKYLAMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS INCYTE CORPORATION (US) 2014-06-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140155377-A1 3-CYCLOALKYLAMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS CCR2, CCR5, CXCR3 ATM 3115/4885DPP4 3229/4885DPP8 3589/4885
US-20150231114-A1 3-CYCLOALKYLAMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS CCR2, CCR5, CXCR3 ATM 3129/4885DPP4 3431/4885DPP8 3848/4885
US-20170050942-A1 3-CYCLOALKYLAMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS CCR2, CCR5, CXCR3 ATM 3056/4885DPP4 3228/4885DPP8 3616/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.